AI Drug Discovery Held Back by Lack of Human Data, Startup Says

Vivodyne, a startup spun out of Penn with about $80M from Khosla Ventures, says AI drug-discovery tools lack real human data, not computing power. CEO Andrei Georgescu warns that without better data, AI will only cure cancer in mice. About 90% of drugs that pass animal tests fail in humans. Anthropic's Dario Amodei has called AI cancer-cure claims more cliche than credible.